Chronic inflammatory demyelinating polyneuropathy pipeline is expected to grow in the next few years on account of increasing prevalence of the disease, which is noticed by progressive muscle weakness, loss of deep tendon reflexes, abnormal sensations, etc. According to a study conducted by American Association of Neuromuscular & Electrodiagnostic Medicine, around 40,000 people in the U.S. get affected from the disease, every year. High prevalence of chronic inflammatory demyelinating polyneuropathy is in turn compelling the government agencies and pharmaceutical companies to promote research and development activities for facilitating growth of the pipeline.
Chronic inflammatory demyelinating polyneuropathy is an inflammatory disorder, which affectsthe peripheral nervous system. The diseaseis caused due to the damage of fatty covering myelin sheath that covers and protects nerve fibers.Occurrence of the disease is more common in males as compared to females. Sometimes it is also called as “chronic relapsing polyneuropathy”,whichis closely related to guillain-barre syndrome, because in both the cases the nervous system gets affected. However, in both the cases, the symptoms are not the same for everyone, and can vary from person to person. Some of the common symptoms of the disease includefatigue, pain, weakness, numbness, etc.
In 2017, Mitsubishi Tanabe pharmaceutical provided license to Novartis Inc., to conduct clinical trials on fingolimod in Switzerland only. All the drugs (including “fingolimod”, “Hyqvia” & “I10E”) have the efficacy to treat chronic inflammatory demyelinating polyneuropathy.
Some of the companies having a pipeline of chronic inflammatory deyelinating polyneuropathy therapeutic include Shire Inc., LB Biotechnologies., Pfizer Inc., Novartis N.V., Eliy-lilly& Company, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Mitsubishi Tanabe Pharma Corporation.